GSK South Africa. “Our global quest is to improve the quality of human life by enabling people to do more, feel better and live longer” GlaxoSmithKline.

GSK South Africa

“Our global quest is to improve the qualityof human life by enabling people to do more,

feel better and live longer”

GlaxoSmithKline Mission...

GSK Biologicals: 2005 Global Business

> £1,196 billion 200511% growth

> 50% US and Europe Infants

InfanrixEvery Second:45 doses of vaccines delivered

N°1 Provider

23% world Market Share

(2004)

GSK Biologicals: Contributing to World Health

We are a primary supplier to international organizations

We provide vaccines to developing world at preferential prices

We distributed approximately 90% of our vaccine doses to the developing world in 2006

– More than 1.5 billion doses of GSK vaccines were distributed worldwide

We work with policy-makers to establish vaccination policies and ensure vaccines are available to all

Worldwide Market Share of Vaccine Companies in 2005

Total Market: £ 5.2 billion

Source: GSK Bio estimates based on analyst reports and company press release

Other18%

Novartis5%

Merck11%

GSK23%

Wyeth13%

Sanofi Pasteur

21%

SP-MSD JV9%

Vaccine DevelopmentLong Lead Times and Big Investment - GSK Bio Core competencies

Identify Antigens

Produce Antigens

Test in Animals

Proof of Concept

Phase I III File

x

Registration

xup to £5.5m up to £30m £250m-500m

x x 3-5 yrs 2-3yrs 2-4 yrs 1 yr

x

Transfer Process to Manufacturing

Build Facility

II

Research (Inc. Immunology)

Preclinical Development (Inc. Formulation Science)

Clinical Development (Inc Post Marketing Surveillance

GSK Bio Milestones - 1956-2005

1956 Killed polio vaccine (Salk™ type: injectable)

1961 Live attenuated polio vaccine (Sabin™ type: oral)

1969 Rubella vaccine WORLD FIRST

1976 Thermostable measles vaccine WORLD FIRST

1984 Varicella vaccine WORLD FIRST

1986 Recombinant hepatitis B vaccine WORLD FIRST

1992 Hepatitis A vaccine WORLD FIRST

1992 Influenza vaccine (from SSW)

1994 Acellular pertussis vaccine (DTPa)

1996 Combined DTPw HBV ± Hib WORLD FIRST

1996 Combined hepatitis A&B WORLD FIRST

1997 Combined DTPa/Hib and DTPa IPV WORLD FIRST

1997 Priorix

1998 Combined DTPa IPV Hib vaccine

1999 DTPa booster vaccine

2000 DTPa HBV IPV (PeNta) (EU) WORLD FIRST

2000 DTPa HBV IPV/ Hib (Hexa)

2000 Combined Hepatitis A & Typhoid WORLD FIRST

2002 DTPa HBV IPV (Pediarix) (US)

2003 Combined meningitis ACW135 WORLD FIRST

2005 Rotavirus vaccine launch in Mexico

GSK Bio Milestones - 1956-2005 (cont’d)

Recent Launches In South Africa

Rotarix – vaccine to prevent Rota Virus GE

– Launched 2006 Vaccinated about 15 000 babies so far Prevented about 1000 hospitalizations

Infanrix Hexa

– Launched January 2007

– Six vaccines in one injection DTPa IPV Hib HB

Pipe line

HPV Candidate Vaccine

Incidence in Africa Mortality in Africa

HPV

The main cause of Cervical Cancer is HPV

Globally types 16, 18, 45 and 31 together account for more than 80% of Cervical Cancer cases

HPV

Up to 80% of women will be infected by an HPV infection at some point in their lives

Following HPV infection, your body does not always develop immunity and is therefore not protected against future infections.

Screening

Screening is the only way to prevent pre-cancerous lesions or the early signs of Cervical Cancer making it easier to treat successfully. However screening cannot prevent the cause of Cervical Cancer

Thank you